
Abemaciclib Combinations Demonstrate Long-Term Disease Control in HR+ Breast Cancer
Published: | Updated:
In a recent study, abemaciclib demonstrated clinical activity both alone and in combinations in women with HR+ metastatic breast cancer.

In a recent study, abemaciclib demonstrated clinical activity both alone and in combinations in women with HR+ metastatic breast cancer.

Published: October 19th 2016 | Updated: December 20th 2020